Prognostic Relevance of Ischemic Late Gadolinium Enhancement in Apparently Healthy Endurance Athletes: A Follow-up Study Over 5 years.
Journal
Sports medicine - open
ISSN: 2199-1170
Titre abrégé: Sports Med Open
Pays: Switzerland
ID NLM: 101662568
Informations de publication
Date de publication:
29 Jan 2024
29 Jan 2024
Historique:
received:
04
08
2023
accepted:
14
01
2024
medline:
29
1
2024
pubmed:
29
1
2024
entrez:
28
1
2024
Statut:
epublish
Résumé
In many cardiac diseases, myocardial scar tissue detected by late gadolinium enhancement (LGE) is a risk factor for cardiac arrhythmia and sudden cardiac death. Previous studies in athletes reported an increased risk for cardiac events in this group of ostensibly healthy subjects. However, the currently available longitudinal studies on this topic included fairly old marathon runners with a mean age of 57 ± 6 years or represent a case-control study in athletes with preexisting ventricular arrhythmia. The purpose of this prospective study was to analyze the prognostic relevance of LGE cardiac magnetic resonance (CMR) in middle-aged endurance athletes without known preexisting cardiac disorders. Three-hundred and twelve apparently healthy athletes were prospectively enrolled. Inclusion criteria were a training for a minimum of 10 h per week and regularly participation in competitions. LGE CMR was obtained at baseline in all athletes and presence of LGE was classified visually according to established criteria as ischemic LGE, major or minor non-ischemic LGE or absent LGE. Follow-up consisted of a standardized questionnaire and an additional phone call in case of incomplete data. An event was defined as fatal myocardial infarction, ventricular tachycardia, ventricular fibrillation or sudden cardiac death (SCD). Complete follow-up was available for 293/312 athletes (94%) including 145 triathletes, 74 marathon runners and 74 cyclists after a median of 5.6 [quartiles 4,3, 6,4] years. Median age was 44 [35, 50] years at study enrollment. Spiroergometry did not reveal heart rhythm disturbances or significant ECG changes in the study population. LGE CMR revealed myocardial scar/focal fibrosis in 80 of 293 athletes (27%) including 7 athletes (2%) with ischemic subendocardial LGE of the left ventricle (LV), 16 athletes (6%) with major non-ischemic LGE of the LV and 57 athletes (19%) with minor non-ischemic LGE. During follow-up, two athletes experienced SCD. One marathon runner died during a training run and one cyclist died suddenly at rest. Both athletes had ischemic LGE of the LV. The event rate for SCD was 0.7% in the entire study population and 28% in the 7 athletes with ischemic LGE (p < 0.001 compared to athletes without LGE). Our findings indicate that athletes with ischemic LGE due to unrecognized myocardial infarction are at increased risk for SCD. Our findings highlight the value of LGE CMR to detect occult ischemic scar in asymptomatic apparently healthy athletes, which is of importance, since current guidelines do not recommend to incorporate routine cardiac imaging in pre-participation screening. Athletes with ischemic myocardial scar should at least consider to refrain from high-level exercise as an individual decision.
Sections du résumé
BACKGROUND
BACKGROUND
In many cardiac diseases, myocardial scar tissue detected by late gadolinium enhancement (LGE) is a risk factor for cardiac arrhythmia and sudden cardiac death. Previous studies in athletes reported an increased risk for cardiac events in this group of ostensibly healthy subjects. However, the currently available longitudinal studies on this topic included fairly old marathon runners with a mean age of 57 ± 6 years or represent a case-control study in athletes with preexisting ventricular arrhythmia. The purpose of this prospective study was to analyze the prognostic relevance of LGE cardiac magnetic resonance (CMR) in middle-aged endurance athletes without known preexisting cardiac disorders.
METHODS
METHODS
Three-hundred and twelve apparently healthy athletes were prospectively enrolled. Inclusion criteria were a training for a minimum of 10 h per week and regularly participation in competitions. LGE CMR was obtained at baseline in all athletes and presence of LGE was classified visually according to established criteria as ischemic LGE, major or minor non-ischemic LGE or absent LGE. Follow-up consisted of a standardized questionnaire and an additional phone call in case of incomplete data. An event was defined as fatal myocardial infarction, ventricular tachycardia, ventricular fibrillation or sudden cardiac death (SCD).
RESULTS
RESULTS
Complete follow-up was available for 293/312 athletes (94%) including 145 triathletes, 74 marathon runners and 74 cyclists after a median of 5.6 [quartiles 4,3, 6,4] years. Median age was 44 [35, 50] years at study enrollment. Spiroergometry did not reveal heart rhythm disturbances or significant ECG changes in the study population. LGE CMR revealed myocardial scar/focal fibrosis in 80 of 293 athletes (27%) including 7 athletes (2%) with ischemic subendocardial LGE of the left ventricle (LV), 16 athletes (6%) with major non-ischemic LGE of the LV and 57 athletes (19%) with minor non-ischemic LGE. During follow-up, two athletes experienced SCD. One marathon runner died during a training run and one cyclist died suddenly at rest. Both athletes had ischemic LGE of the LV. The event rate for SCD was 0.7% in the entire study population and 28% in the 7 athletes with ischemic LGE (p < 0.001 compared to athletes without LGE).
CONCLUSIONS
CONCLUSIONS
Our findings indicate that athletes with ischemic LGE due to unrecognized myocardial infarction are at increased risk for SCD. Our findings highlight the value of LGE CMR to detect occult ischemic scar in asymptomatic apparently healthy athletes, which is of importance, since current guidelines do not recommend to incorporate routine cardiac imaging in pre-participation screening. Athletes with ischemic myocardial scar should at least consider to refrain from high-level exercise as an individual decision.
Identifiants
pubmed: 38282168
doi: 10.1186/s40798-024-00680-1
pii: 10.1186/s40798-024-00680-1
doi:
Types de publication
Journal Article
Langues
eng
Pagination
13Informations de copyright
© 2024. The Author(s).
Références
Patel AR, Kramer CM. Role of cardiac magnetic resonance in the diagnosis and prognosis of nonischemic cardiomyopathy. Jacc Cardiovasc Imaging. 2017;10(10):1180–93. https://doi.org/10.1016/j.jcmg.2017.08.005 .
doi: 10.1016/j.jcmg.2017.08.005
pubmed: 28982571
pmcid: 5708889
Breuckmann F, Möhlenkamp S, Nassenstein K, et al. Myocardial late gadolinium enhancement: prevalence, pattern, and prognostic relevance in marathon runners. Radiology. 2009;251(1):50–7. https://doi.org/10.1148/radiol.2511081118 .
doi: 10.1148/radiol.2511081118
pubmed: 19332846
Zorzi A, Marra MP, Rigato I, et al. Nonischemic Left ventricular scar as a substrate of life-threatening ventricular arrhythmias and sudden cardiac death in competitive athletes. Circ Arrhythm Electrophysiol. 2016;9(7):e506–74. https://doi.org/10.1161/circep.116.004229 .
doi: 10.1161/circep.116.004229
Tahir E, Starekova J, Muellerleile K, et al. Myocardial fibrosis in competitive triathletes detected by contrast-enhanced CMR correlates With exercise-induced hypertension and competition history. JACC Cardiovasc Imaging. 2018;11(9):1260–70. https://doi.org/10.1016/j.jcmg.2017.09.016 .
doi: 10.1016/j.jcmg.2017.09.016
pubmed: 29248656
Ragab H, Lund GK, Breitsprecher L, et al. Prevalence and pattern of focal and potential diffuse myocardial fibrosis in male and female marathon runners using contrast-enhanced cardiac magnetic resonance. Eur Radiol. 2023;33(7):4648–56. https://doi.org/10.1007/s00330-023-09416-3 .
doi: 10.1007/s00330-023-09416-3
pubmed: 36683089
pmcid: 10289973
Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European Countries, Canada, and the United States. JAMA. 2003;289(18):2363–9. https://doi.org/10.1001/jama.289.18.2363 .
doi: 10.1001/jama.289.18.2363
pubmed: 12746359
Schultz MG, Otahal P, Cleland VJ, Blizzard L, Marwick TH, Sharman JE. Exercise-induced hypertension, cardiovascular events, and mortality in patients undergoing exercise stress testing: a systematic review and meta-analysis. Am J Hypertens. 2013;26(3):357–66. https://doi.org/10.1093/ajh/hps053 .
doi: 10.1093/ajh/hps053
pubmed: 23382486
Tahir E, Starekova J, Muellerleile K, et al. Impact of myocardial fibrosis on left ventricular function evaluated by feature-tracking myocardial strain cardiac magnetic resonance in competitive male triathletes with normal ejection fraction. Circ J. 2019;83(7):1553–62. https://doi.org/10.1253/circj.cj-18-1388 .
doi: 10.1253/circj.cj-18-1388
pubmed: 31080228
Schulz-Menger J, Bluemke DA, Bremerich J, et al. Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magnetic Reson. 2013;15(1):35. https://doi.org/10.1186/1532-429x-15-35 .
doi: 10.1186/1532-429x-15-35
Shanbhag SM, Greve AM, Aspelund T, et al. Prevalence and prognosis of ischaemic and non-ischaemic myocardial fibrosis in older adults. Eur Heart J. 2018;40(6):529–38. https://doi.org/10.1093/eurheartj/ehy713 .
doi: 10.1093/eurheartj/ehy713
pmcid: 6657269
Halle M, Esefeld K, Schindler M, Schunkert H. Exercise hypertension: Link to myocardial fibrosis in athletes? Eur J Prev Cardiol. 2019;27(1):89–93. https://doi.org/10.1177/2047487319868795 .
doi: 10.1177/2047487319868795
pubmed: 31412714
Klem I, Weinsaft JW, Bahnson TD, et al. Assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. J Am Coll Cardiol. 2012;60(5):408–20. https://doi.org/10.1016/j.jacc.2012.02.070 .
doi: 10.1016/j.jacc.2012.02.070
pubmed: 22835669
pmcid: 3424733
Pelliccia A, Sharma S, Gati S, et al. ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease The Task Force on sports cardiology and exercise in patients with cardiovascular disease of the European Society of Cardiology (ESC). Eur Heart J. 2020;2020:ehaa605. https://doi.org/10.1093/eurheartj/ehaa605 .
doi: 10.1093/eurheartj/ehaa605